Xceleron’s enhanced Phase I clinical trials give fuller insights into human disposition, bioavailability and metabolism, for an incremental cost on a typical clinical study. Using slightly modified clinical designs, we can provide critical ADME and PK data much earlier in the drug development process than when traditional approaches are used.
Our enhanced Phase I studies do not require additional safety or dosimetry data over traditional Phase I clinical trials. As a result, when 14C-labeled drug is available (as it typically is from preclinical studies), we can generate valuable human disposition, bioavailability or metabolism data within existing drug development timelines.
Drug researchers can gain access to this data years earlier than they would using traditional clinical studies, and can do it for a fraction of the cost with AMS-enabled studies.
Xceleron’s enhanced Phase I Studies have been used to:
Click here to read more about human metabolite profiling in Phase I.
See our IVPK Studies for a cost effective way to gain early bioavailability data.
Pharmaron Acquires Majority Stake in SNBL CPC
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.